• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Simultaneous blockade of TIGIT and HIF-1 α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells
CONCLUSIONS: Present data suggest the combination treatment of TIGIT and HIF-1α as a novel treatment strategy against colorectal and breast cancer, but more researches are required to realize the complete role of TIGIT and HIF-1α inside the TME.PMID:34710844 | DOI:10.1016/j.intimp.2021.108288
Source: International Immunopharmacology - October 28, 2021 Category: Allergy & Immunology Authors: Mehrdad Fathi Simin Bahmanpour Asal Barshidi Hossein Rasouli Fariba Karoon Kiani Armin Mahmoud Salehi Khesht Sepideh Izadi Bentolhoda Rashidi Shiva Kermanpour Roya Mokhtarian Vahid Karpisheh Hadi Hassannia Hamed Mohammadi Ali Jalili Farhad Jadidi-Niaragh Source Type: research

NF κB and Kidney Injury
Conclusion As a critical regulator of inflammation and cell survival, the NFκB pathway is a promising target for diagnosing and treating kidney diseases. For modulation of the NFκB pathway in the clinic, a number of molecules can effectively inhibit NFκB signaling by targeting the receptors, associated adaptors, IKKs, IκBs and transcriptional regulators (144). There is further clinical evidence on small-molecule inhibitors of IKKα and NIK from recent trials on anti-cancer therapies (145). These clinical trials showed that the cancer-selective pharmacodynamic response of DTP3, the co...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research